Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 40 of 750 for:    Area Under Curve AND meal

The Effect of Sitting and Moderate Exercise on Plasma Triglyceride Elevation After a Meal

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03098446
Recruitment Status : Completed
First Posted : March 31, 2017
Last Update Posted : October 5, 2018
Sponsor:
Information provided by (Responsible Party):
Edward F. Coyle, University of Texas at Austin

Brief Summary:
The purpose of this study is to investigate the effect of 4 days of sitting and moderate exercise on plasma triglyceride elevation after a meal.

Condition or disease Intervention/treatment Phase
Atherosclerosis Metabolic Syndrome Behavioral: Prolonged sitting with exercise Behavioral: Prolonged sitting without exercise Not Applicable

Detailed Description:
Subjects will undergo three weeks (two intervention, one washout) of testing during which they will participate in two conditions: 1) prolonged sitting (~14-hours/day) with a 1-hour bout of acute exercise at 65% of pre-intervention VO2max and 2) prolonged sitting (~14-hours/day) without an acute bout of exercise. During each intervention week, subjects will have 2 days of dietary and activity control, followed by 4 days during which prolonged sitting will occur. On the evening of the 4th day, subjects in the exercise group will perform the acute bout of exercise. On day 5, all subjects will undergo a lipid tolerance test to determine the body's ability to clear triglycerides from the blood as well as insulin/glucose response and substrate oxidation. Blood samples will be assayed for the previously mentioned substances and postprandial gas collection will be analyzed via indirect calorimetry.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Subjects will be randomly assigned to either the sitting plus exercise or the sitting without exercise group and then, after a one week washout period, complete the other task.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: The Effect of Sitting and Moderate Exercise on Plasma Triglyceride Elevation After a Meal
Actual Study Start Date : April 8, 2017
Actual Primary Completion Date : August 11, 2017
Actual Study Completion Date : August 11, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Prolonged sitting with exercise
Subjects will be asked to undergo prolonged sitting (~14-hours/day) for 4 days. On the evening of day 4, they will be asked to run at 65% of VO2max for 1-hour.
Behavioral: Prolonged sitting with exercise
Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial with the acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.

Experimental: Prolonged sitting without exercise
Subjects will be asked to undergo prolonged sitting (~14-hours/day) for 4 days. Subjects will not be asked to complete the acute bout of exercise to serve as a control.
Behavioral: Prolonged sitting without exercise
Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial, but will not be asked to complete an acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.




Primary Outcome Measures :
  1. Plasma Triglycerides [ Time Frame: 6-hours ]
    Areas under the curve for triglyceride concentration will be calculated for hourly samples from a 6-hour lipid tolerance test


Secondary Outcome Measures :
  1. Plasma Insulin [ Time Frame: 6-hours ]
    Areas under the curve for insulin concentration will be calculated for hourly samples from a 6-hour lipid tolerance test

  2. Plasma Glucose [ Time Frame: 6-hours ]
    Areas under the curve for glucose concentration will be calculated for hourly samples from a 6-hour lipid tolerance test



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

-

Exclusion Criteria:

  • cardiovascular problems (e.g. pre-existing heart issues, coronary artery disease, hypertension, etc.)
  • respiratory problems
  • musculoskeletal problems that prevent prolonged sitting or exercise
  • obesity
  • susceptibility to fainting

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03098446


Locations
Layout table for location information
United States, Texas
University of Texas at Austin Human Performance Laboratory
Austin, Texas, United States, 78712
Sponsors and Collaborators
University of Texas at Austin

Layout table for additonal information
Responsible Party: Edward F. Coyle, Professor, University of Texas at Austin
ClinicalTrials.gov Identifier: NCT03098446     History of Changes
Other Study ID Numbers: 2016-12-0022
First Posted: March 31, 2017    Key Record Dates
Last Update Posted: October 5, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Atherosclerosis
Metabolic Syndrome
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases